Jabbour, E <br/><br/>
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.  [electronic resource] 

 -  Leukemia  Feb 2011 
 - 201-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2010.215  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides<br/>Dasatinib<br/>Disease Management<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--complications<br/>Piperazines--adverse effects<br/>Protein Kinase Inhibitors--adverse effects<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--adverse effects<br/>Thiazoles--adverse effects